LIDDS announces closure of R&D project with Johnson & Johnson Enterprise Innovation Inc.

Regulatory

UPPSALA, SWEDEN – LIDDS AB (publ) announces today that the company has closed the on-going R&D collaboration project with Johnson & Johnson Enterprise Innovation Inc. following completion of all activities and delivery of its final report.

Following the recent Joint Research Committee, at which the LIDDS team delivered their final report from the collaboration, Johnson & Johnson Enterprise Innovation Inc. communicated its decision to not continue any further development activities at this time. The collaboration was formed in 2021 with the aim to develop an oncology product based on the NanoZolid® technology for an undisclosed indication.

“It has been a pleasure to collaborate with Johnson & Johnson Enterprise Innovation and the work we’ve completed has further built on our understanding of the NanoZolid® technology” says Matthew Lindon, Chief Scientific Officer at LIDDS. “We will take the many positive learnings from this work, and we remain open to new partnerships in the future.”

For additional information, please contact

Anders Månsson, CEO
Phone: +46 (0)70 860 47 38
E-mail: anders.mansson@liddspharma.com
 
Jenni Björnulfson, CFO
Phone: +46 (0)70 855 38 05
E-mail: jenni.bjornulfson@liddspharma.com

LIDDS’s Certified Adviser is Redeye AB

This information is information that LIDDS is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2023-07-06 22:30 CEST.

LIDDS in brief:

LIDDS is a Swedish drug delivery company based on the proprietary technology NanoZolid®. With NanoZolid®, LIDDS can formulate drugs for local/intratumoral administration, with a maintained and controlled release for up to six months. The technology is versatile, can be used across different drug classes and can solve problems within many indication areas, mainly within oncology. LIDDS offers the NanoZolid® technology to partners and has developed its own pipeline focused on oncology, where the technology enables delivery of a local and high drug dose, administered over time with very limited side effects. LIDDS has a broad pipeline with several projects in clinical development, both in early and late-stage clinical phase, and projects about to enter clinical development. The company is listed on Nasdaq First North Growth Market.

Attachments

LIDDS announces closure of R&D project with Johnson & Johnson Enterprise Innovation Inc.